The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry.

OBJECTIVES: This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselec...

Full description

Bibliographic Details
Main Authors:	Abizaid, A, Costa, JR, Banning, A, Bartorelli, A, Dzavik, V, Ellis, S, Gao, R, Holmes, DR, Jeong, M, Legrand, V, Neumann, F, Nyakern, M, Orlick, A, Spaulding, C, Worthley, S, Urban, P
Format:	Journal article
Language:	English
Published:	2012

The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry.

Similar Items